Search clinical trials for: PegIFN alfa-2a

Total 3338 results

The Second Affiliated Hospital of Chongqing Medical...
The First Affiliated Hospital of Nanchang University; First Affiliated Hospital... and other collaborators

Unknown

Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides

Hepatitis B
Huashan Hospital

Unknown

Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy

Chronic Hepatitis B

China
Huashan Hospital

Completed

Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy

Chronic Hepatitis B

China
Bristol-Myers Squibb

Completed

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen (LIRA-B)

Hepatitis B Virus

Australia, France, Germany, Korea, Republic of, Taiwan, United States, Canada, Italy, Netherlands, Singapore, Hong Kong
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Completed

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen (TelapreVIH)

HIV Infection | Hepatitis C, Chronic

France
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants (QUEST-2)

Hepatitis C

United States, France, Poland, Belgium, Germany, Spain, Portugal, Bulgaria, Turkey, Argentina, Brazil, Austria, Netherlands, Slovakia, Puerto Rico
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

Hepatitis C, Chronic

Japan
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients (QUEST-1)

Hepatitis C

United States, Australia, Ukraine, United Kingdom, Germany, Spain, Mexico, Canada, New Zealand, Russian Federation, Puerto Rico, Romania
Janssen R&D Ireland

Completed

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy (PROMISE)

Hepatitis C

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, New Zealand, Russian Federation, Puerto Rico, Austria
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Hepatitis B, Chronic

Russian Federation
Hoffmann-La Roche

Completed

A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

Hepatitis B, Chronic

Taiwan, United States, New Zealand, Singapore
The Second Affiliated Hospital of Chongqing Medical...

Unknown

A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA <200IU/ml (New Switch)

Chronic Hepatitis B

China
Hoffmann-La Roche

Terminated

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.

Hepatitis B, Chronic

Turkey
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

China, Hong Kong, Australia, Germany, Taiwan, Singapore, France, United States, Korea, Republic of, New Zealand, Thailand, Russian Federation, Brazil
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.

Hepatitis C, Chronic

Russian Federation
Chugai Pharmaceutical

Completed

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C

Chronic Hepatitis C
Third Affiliated Hospital, Sun Yat-Sen University
Peking University; Huazhong University of Science and Technology; First People... and other collaborators

Unknown

The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg

Chronic Hepatitis B

China
Hoffmann-La Roche

Completed

Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253

Hepatitis B, Chronic

Italy
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy

Hepatitis B

China
Third Affiliated Hospital, Sun Yat-Sen University
Peking University; Huazhong University of Science and Technology; First People... and other collaborators

Unknown

HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients

Chronic Hepatitis B

China
Hoffmann-La Roche

Completed

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Hepatitis C, Chronic

Israel
Hoffmann-La Roche

Completed

A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy

Hepatitis C, Chronic

Germany
Beijing 302 Hospital

Unknown

Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Ruijin Hospital

Unknown

An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

Chronic Hepatitis B
National Institute of Diabetes and Digestive and...

Not yet recruiting

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

Chronic Hepatitis B

United States
Seng Gee Lim
Roche Pharma AG

Unknown

Peg-interferon for Inactive Chronic Hepatitis B Carriers (INACTIVE)

Chronic Hepatitis, B Virus | Carrier of Viral Hepatitis Type B

Singapore
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Hoffmann-La Roche

Completed

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Hepatitis C, Chronic

United States
Hoffmann-La Roche

Completed

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

China, Hong Kong, Taiwan, Singapore, Korea, Republic of, New Zealand, Thailand, Brazil, Russian Federation, Australia
The Catholic University of Korea
Ulsan University Hospital; Yonsei University; Kyungpook National University Hospital and other collaborators

Completed

100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)

Sustained Virologic Response | IL28B Polymorphism

Korea, Republic of
Hoffmann-La Roche

Completed

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

United States, Puerto Rico
Beijing Ditan Hospital

Unknown

The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Janssen Pharmaceutical K.K.

Completed

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Hepatitis C, Chronic

Japan
Janssen-Cilag International NV

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Hepatitis C, Chronic | Infection

United Kingdom, Germany, Spain, Belgium, Saudi Arabia, Austria, France
Foundation for Liver Research

Completed

Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB (PEGON)

Chronic Hepatitis B

Netherlands, China
Merck Sharp & Dohme LLC

Terminated

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

Malignant Melanoma
Hoffmann-La Roche

Completed

PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Hepatitis C, Chronic

Belgium, Ireland, Italy, United Kingdom
Hoffmann-La Roche

Completed

An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B

Hepatitis B, Chronic

Morocco
Hoffmann-La Roche

Completed

PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

France, Sweden, Austria, Hungary, Poland, Romania, Slovenia, Croatia, Serbia, Canada, Brazil, Morocco, Mexico, Macedonia, The Former Yugoslav Republic of
Third Affiliated Hospital, Sun Yat-Sen University

Completed

Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

Antiviral Treatment of Chronic Hepatitis B
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers

Chronic Viral Hepatitis C

Brazil
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Hepatitis B, Chronic

Bulgaria
Gilead Sciences

Completed

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Chronic Hepatitis Delta

France, Moldova, Republic of, Romania, Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Breast Cancer | Metastatic Cancer

United States
Alios Biopharma Inc.

Withdrawn

A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

Hepatitis B, Chronic
Yao Xie

Unknown

The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China

3

Subscribe